SCHEMBL23219235

SCHEMBL23219235

CCOC(=O)Cc1ccccc1OCc1nsc2ccc(Br)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 1/20 0.42
CFD P00746 1/20 0.42
CSNK1D P48730 1/20 0.37
PTGER1 P34995 4/20 0.36
DPP4 P27487 2/20 0.36
LMNA P02545 2/20 0.36
TP53 P04637 2/20 0.36
PKM P14618 2/20 0.36
JAK2 O60674 1/20 0.36
PAK4 O96013 1/20 0.36
NTRK1 P04629 1/20 0.36
LCK P06239 1/20 0.36
FYN P06241 1/20 0.36
CSF1R P07333 1/20 0.36
RET P07949 1/20 0.36
MET P08581 1/20 0.36
PDGFRB P09619 1/20 0.36
PIM1 P11309 1/20 0.36
FGFR1 P11362 1/20 0.36
PRKACA P17612 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852906 1.00 TBXAS1 (0.42) TBXAS1CFDCSNK1DPTGER1DPP4
SCHEMBL23218709 0.82 CFD (0.59) TBXAS1CFDDPP4PKMSMN1; SMN2
SCHEMBL29853262 0.82 CFD (0.59) TBXAS1CFDDPP4PKMSMN1; SMN2
SCHEMBL23219015 0.82 ALDH1A1 (0.44) TBXAS1CFDCSNK1DPTGER1DPP4
SCHEMBL23219162 0.80 MAPT (0.46) TBXAS1CFDPTGER1DPP4LMNA
SCHEMBL29591729 0.79 CFD (0.47) TBXAS1CFDPTGER1DPP4LMNA
SCHEMBL23218172 0.79 CFD (0.47) TBXAS1CFDPTGER1DPP4LMNA
SCHEMBL23218871 0.78 MAPT (0.42) TBXAS1CFDCSNK1DLMNATP53
SCHEMBL29121850 0.78 CFD (0.47) TBXAS1CFDPTGER1JAK2PAK4
SCHEMBL29122620 0.78 CFD (0.47) TBXAS1CFDPTGER1LMNAJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TBXAS1 963/4885CFD 1/4885CSNK1D 294/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TBXAS1 392/4885CFD 1/4885CSNK1D 1517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.